ArticleThe Journal of investigative dermatology2022
Molecular and Cellular Characterization of Pyoderma Gangrenosum: Implications for the Use of Gene Expression.
2 registry-linked trialsAbstract read
In one paragraph
Article in The Journal of investigative dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07767864 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation
A Single-arm Open-label Study Assessing Efficacy of Bimekizumab in Adult Participants With Pyoderma Gangrenosum Over 24 Weeks
NCT07783412 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation
Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Human Inborn Errors of Immunity in Pyoderma Gangrenosum: A Systematic Review.American journal of clinical dermatology · 2024Pooled it
- Pyoderma gangrenosum caused by the molecular uncoupling of OTULIN catalytic activity and LUBAC binding.Nature immunology · 2026Article
- Integrative Multi-Omics Analysis and Computational Modeling Identifying Shared Inflammatory Pathways and JAK Inhibitor Targets in PG and IBD.International journal of molecular sciences · 2026Article
- Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment.Seminars in immunopathology · 2025Review
- IL-12/IL-23 Blockade Reveals Patterns of Asynchronous Inflammation in Pyoderma Gangrenosum.The Journal of investigative dermatology · 2025Article
- Gasdermin D-dependent neutrophil extracellular traps exacerbate cytokine storm contributing to pyoderma gangrenosum pathogenesis.iScience · 2025Article
- Real-world safety and effectiveness of adalimumab in patients with pyoderma gangrenosum: Interim analysis of a post-marketing observational study in Japan.The Journal of dermatology · 2025Observational
- Article
- Case Report: Treatment of facial pyoderma gangrenosum with Upadacitinib.Frontiers in medicine · 2025Article
- Secukinumab treatment in a pediatric patient with corticosteroid-intolerant pyoderma gangrenosum: a case report.Frontiers in medicine · 2025Article
- Monoclonal Antibodies in the Management of Inflammation in Wound Healing: An Updated Literature Review.Journal of clinical medicine · 2024Review
- Ustekinumab for pyoderma gangrenosum-like skin ulcerations in late-onset leukocyte adhesion deficiency.The journal of allergy and clinical immunology. Global · 2024Article
- New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.The Journal of dermatology · 2024Review
- NETosis Is Induced by Complement Component 5a: Implications in the Pathogenesis of Pyoderma Gangrenosum.The Journal of investigative dermatology · 2024Article
- Narrative Review: Pyoderma Gangrenosum.Cureus · 2024Review
- What can inherited immunodeficiencies reveal about pyoderma gangrenosum?Experimental dermatology · 2024Review
- Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report.Acta dermato-venereologica · 2023Article
- Resolution of therapy-resistant pyoderma gangrenosum with upadacitinib.JAAD case reports · 2023Article
- The "Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)" Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum.Archives of dermatological research · 2023Article
- Different molecular pathways are disrupted in Pyoderma gangrenosum patients and are associated with the severity of the disease.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Alex G Ortega-LoayzaDepartment of Dermatology, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA. Electronic address: ortegalo@ohsu.edu.
Marcia A FriedmanDivision of Arthritis and Rheumatic Diseases, Department of Medicine, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Ashley M ReeseDepartment of Dermatology, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Yuangang LiuDepartment of Dermatology, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Teri M GreilingDepartment of Dermatology, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Pamela B CassidyDepartment of Dermatology, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Angelo V MarzanoDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Lina GaoBioinformatics and Biostatistics Core, Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, USA.
Suzanne S FeiBioinformatics and Biostatistics Core, Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, USA.
James T RosenbaumDivision of Arthritis and Rheumatic Diseases, Department of Medicine, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Funding
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9MOregon Clinical and Translational Research Institute KL2 SupplementKL2TR002370 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Catherine Lee Hough · 2017 to 2026
$10.1MGene Expression in Nonspecific Orbital Inflammatory DiseaseR01EY020249 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI ROSENBAUM, JAMES T · 2011 to 2020
$5.0MTraining in Translational Science and Cardiovascular MedicineT32HL094294 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI ALKAYED, NABIL J · 2009 to 2018
$3.5MNCATS NIH HHS KL2 TR002370NEI NIH HHS R01 EY020249NHLBI NIH HHS T32 HL094294NIH HHS P51 OD011092
Abstract
PubMed holds no abstract for this paper.
Indexed as
Pyoderma GangrenosumGene ExpressionHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07767864ClinicalTrials.gov
NCT07783412ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.